Evaluation of bleeding risk in patients with renal impairment treated with Fondaparinux (Arixtra)

Evaluation of bleeding risk in patients with renal impairment treated with Fondaparinux (Arixtra)

Background: Fondaparinux (Arixtra) a synthetic pentasaccharide that causes an antithrombin III-mediated selective inhibition of factor Xa. The clearance of fondaparinux reduces in patients with renal impairment, and there are no dosage adjustments provided in the manufacturer’s labeling. In patients...

Full description

Bibliographic Details
Main Authors: Hend H Metwali, Mohammed A Aseeri, Ahmed Mahmoud, Ahmad S Alsaeed, Mona E Albdelwahab, Abdul Salam, Rayf Abulezz
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Journal of Applied Hematology
Subjects:
Bleeding risk
fondaparinux
renal impairment
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2016;volume=7;issue=4;spage=131;epage=135;aulast=Metwali

Internet

http://www.jahjournal.org/article.asp?issn=1658-5127;year=2016;volume=7;issue=4;spage=131;epage=135;aulast=Metwali

Similar Items